Clinical Trial Results Home

ST Elevation MI: Fibrinolysis

 Contents
Fibrinolytic Monotherapy
Half Dose Fibrinolytic + Full Dose GPII/IIIa Inhibition
Facilitated PCI
 Fibrinolytic Monotherapy

ASSENT-2: Assessment of the Safety and Efficacy of a New Thrombolytic: Tnk-Tpa-2

      -TNK in STEMI

ASSENT-3: Assessment of the Safety and Efficacy of a New Thrombolytic Regimen - 3 Trial

      -Efficacy and Safety of Tenecteplase in Combination with Enoxaparin, Abciximab or Unfractionated Heparin

ASSENT-3 Plus: Assessment of the Safety and Efficacy of a New Thrombolytic Regimen 3 Plus

      -Low Molecular Weight Heparin Enoxaparin vs. Unfractionated Heparin in Combination with TNK for STEMI

ASSENT-4 PCI: Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction - 4 PCI Trial

      -Trial Overview by Dr. Frans Van de Werf (European Society of Cariology 2005)

CLARITY-TIMI 28: CLopidogrel as Adjunctive ReperfusIon TherapY - Thrombolysis In Myocardial Infarction (TIMI) 28

      -Trial Overview by Dr. Marc Sabatine

COMMIT/CCS-2: ClOpidogrel & Metoprolol in Myocardial Infarction Trial

      -Clopidogrel vs. Placebo Among Patients with ST Elevation Myocardial Infarction (MI) Also Treated with Aspirin

      -Treatment with the Beta-Blocker Metoprolol Compared with Placebo among Patients with STEMI also Treated with Aspirin

CREATE-ECLA-Reviparin: The Clinical Trial of Reviparin and Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation - Estudios Cardiológicos Latinoamérica

      -Phase 2 Study o by Dr. S.D. Yusuf (AHA 2004)

ENTIRE - TIMI 23: Enoxaparin And Tnk-Tpa With Or Without Gp IIb/IIIa Inhibitor As Reperfusion Strategy In St Elevation MI - Thrombolysis In Myocardial Infarction (TIMI) 23

      -Trial Overview

EXTRACT-TIMI 25: Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction - Thrombolysis In Myocardial Infarction (TIMI) 25

      -Trial Overview by Dr. Elliot Antman (ACC 2006)

HART-II: Heart Failure Adherence and Retention Trial II

      -Trial Overview by Dr. A. Ross (ACC 2000)

Lytics

      -Appropriate Use of Lytics: Adherence to the Guidelines by Dr. W. Frank Peacock

MOPETT: Moderate Pulmonary Embolism Treated with Thrombolysis

      -Study Overview by Dr. Mohsen Sharifi (ACC 2012)

TIMI 10A, 10B, ASSENT 1: Thrombolysis In Myocardial Infarction (TIMI) 10A, 10B, Assessment of the Safety and Efficacy of a New Thrombolytic 1

      -TNK in STEMI

(Return to Contents)

 Half Dose Fibrinolytic + Full Dose GPII/IIIa Inhibition

FASTER: Fibrinolytic and Aggrastat ST Elevation Resolution Trial

      -Aggrastat in STEMI

GUSTO-IV AMI: Global Use of Strategies To open Occluded coronary arteries in AMI

      -Trial Design: rPA + abciximab vs rPA alone in STEMI

INTEGRITI: Integrilin and Tenecteplase in Acute Myocardial Infarction

      -Eptifibatide + TNK in STEMI by Dr. RP Giugliano

INTRO AMI: INTegrilin and Reduced dose Of thrombolytic in Acute Myocardial Infarction

      -Rationale: Eptifibatide + lysis in STEMI

      -Results: Eptifibatide + lysis in STEMI

SPEED: Strategies for Patency Enhancement in the Emergency Department

      -rPA + abciximab

TIMI 14: Thrombolysis In Myocardial Infarction (TIMI) 14

      -rPA + abciximab in STEMI

(Return to Contents)

 Facilitated PCI

ADMIRAL: Abciximab before Direct angioplasty and stenting in Myocardial Infarction Regarding Acute and Long term follow-up

      -Trial Overview

ADMIRAL vs. CADILLAC: Abciximab before Direct angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up vs. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications Trial

      -Trial Comparison

ADVANCE: The Additive Value of Tirofiban Administered With the High-Dose Bolus in the Prevention of Ischemic Complications During High-Risk Coronary Angioplasty

      -Trial Overview by Dr. M. Valgimigli

CAPITAL AMI: Combined Angioplasty and Pharmacological Intervention Versus Thrombolytics Alone in Acute Myocardial Infarction

      -Trial Overview by Dr. Michel R. Le May (ACC 2004)

GRACIA-2: Grupo de Analisis de la Cardiopatia Isquemica Aguda (Randomized trial comparing stenting within 24 hours of thrombolysis versus ischemia-guided approach to thrombolysed acute myocardial infarction with ST elevation)

      -Primary Optimal Percutaneous Coronary Intervention versus Facilitated Intervention in STEMI Patients (European Society of Cardiology 2003)

ICSK After Primary PCI: Intracoronary Streptokinase after Primary Percutaneous Coronary Intervention

      -Intracoronary Streptokinase after Primary Percutaneous Coronary Intervention by Dr. Murat Sezer

INTAMI: Integrilin in Acute Myocardial Infarction

      -Results by Dr. Uwe Zeymer (2005)

PACT: Plasminogen-Activator Angioplasty Compatibility Trial

      -Trial Overview

REACT: Rescue Angioplasty versus Conservative Therapy or Repeat Thrombolysis Trial

      -6-Month Results by Dr. A. H. Gershlick (AHA 2004)

STRATEGY: Single High-Dose Bolus Tirofiban And Sirolimus-Eluting Stent Vs. Abciximab And Bare-Metal Stent In Myocardial Infarction

      -Trial Overview by Dr. Marco Valgimigli (2005)

TETAMI: Treatment with Enoxaparin and Tirofiban in Acute MI

      -Results by Dr. M. Cohen

TIGER PA: Tirofiban Given in the Emergency Room Before Primary Angioplasty

      -Trial Overview by Dr. David P. Lee

(Return to Contents)

Who Are We?    Slide Downloading Policy   Financial Disclosure    We Do Not Promote Off Label Product Use    Copyright    Source of Slides    Editorial Policy    Links Policy    Privacy Policy   Access    CME Programs

© 1999-2009 by Clinical Trial Results .org.  None of the materials on this website may be reproduced, modified, distributed, transmitted, republished, displayed, or performed unless prior written approval is obtained by Clinical Trial Results.  All such requests should be forwarded to Susan J. Marble at smarble@clinicaltrialresults.org. For further information please see the Policy section. Webmaster